Compare DexCom, Inc. (DXCM) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Manulife Financial Corporation — how do they compare? DexCom, Inc. trades at $84.46 (market cap $31.81B), while Manulife Financial Corporation trades at $43.58 (market cap $69.26B). The key difference: Manulife Financial Corporation is far larger — about 2.2× DexCom, Inc.'s market cap, and Manulife Financial Corporation pays a 3.27% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Manulife Financial Corporation for 119 Days on average.
| DXCM | MFC | |
|---|---|---|
Market Cap | $31.81B | $69.26B |
Volume | 2,861,821 | 1,347,387 |
Sector | Health | Financials |
52-Week High | $92.34 | $44.77 |
52-Week Low | $54.84 | $31.64 |
Typical Hold Time | 62 Days | 119 Days |
Enterprise Value | $31.26B | $64.51B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Manulife Financial (MFC) trades at $42.12, down 1.89% today, with a bearish technical outlook despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and others highlight confidence, while analyst consensus remains positive with 57% buy ratings.
MFC presents a mixed outlook: strong operational performance and dividend yield support upside, but technical indicators signal near-term pressure. Key risks include debt levels and market volatility, while opportunities lie in Asia growth and reinsurance deals. The stock trades above the consensus price target of $34.24, suggesting cautious optimism with execution-dependent returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
